Docoh
Loading...

PHBI Pharmagreen Biotech

Filed: 22 Jun 21, 8:00pm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 21, 2021

 

Pharmagreen Biotech Inc.

(Exact name of registrant as specified in its charter)

 

Nevada

 

333-151350

 

26-1679929

(State or other jurisdiction of incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

  

2987 Blackbear Court, Coquitlam, British Columbia, V3E 3A2 

(Address of Principal Executive Offices) (Zip Code) 

 

702-803-9404 

(Registrant's telephone number, including area code)

 

_______________________________________________ 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Shares

PHBI

OTC Markets

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company [ ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]


 

ITEM 1.01 Entry into a Material Definitive Agreement

Production Services Agreement

 

Effective June 13, 2021, the Company entered into a consulting agreement with Milestone Management Services.  Pursuant to the terms of the agreement, the Milestone Management Services will provide and advise PHBI’s management team regarding any current or potential projects, acquisitions, sales, mergers and any other day to day decision making questions.

 

This Agreement has a 6-month term and will terminate on December 13, 2021. The Company shall issue issuing 117,000 restricted shares of its common stock per month.

 

The description of the transaction contemplated by this agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the documents filed as exhibits hereto and incorporated herein by reference.

SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01 Financial Statements and Exhibits.

Exhibit 99.1Consulting Agreement 

 

 SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 

Pharmagreen Biotech Inc.

 

 

 

 

 

Dated: June 21 2021

By:

/s/ Peter Wojcik

 

 

 

Peter Wojcik

 

 

 

Chief Executive Officer, Director